RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
The invention relates to novel compounds which show high
affinity for cocaine receptors in the brain, particularly dopamine
and serotonin transporter sites. The compounds may be used as
imaging or pharmaceutical agents, in the diagnosis and treatment of
drug addiction, depression, anorexia and neurodegenerative
diseases.